Belongs to the class of granulocyte colony-stimulated factor.
Approved by the FDA to decrease the risk of developing febrile neutropenia and the duration of neutropenia when receiving bone marrow-suppressive chemotherapy drugs.
Indicated to increase survival rate in patients exposed to radiation therapy.
Uses:
Decreases the chance of infection caused by low levels of white blood cells in patients with certain types of cancer receiving bone marrow-suppressing anti-cancer drugs.
Increases the survival rate in patients receiving radiation therapy that suppresses bone marrow activity.
Mechanism of Action:
Acts on blood-forming cells, stimulating cell multiplication and functional activation.
Pegfilgrastim is a protein synthesized through biotechnology in E. coli bacteria.
Important Information:
Inform your physician if you have liver disease, fever or infection, kidney problems, heart problems, or a family history of kidney diseases before starting treatment.
Do not take if allergic to pegfilgrastim, filgrastim, or other ingredients.
Report symptoms of left upper abdominal pain, shoulder pain, and respiratory problems immediately.
Side Effects:
Common: pain in bones, joints, and muscles; pain at the injection site; itchiness and skin rash; nausea; headaches; dizziness and tiredness.
Serious: inflammation of aorta; capillary leak syndrome; hypersensitivity reactions; changes in urine color; swelling in hands, feet, face, and abdomen; difficulty in breathing; sickle cell anemia.
Safety Advice:
Pregnancy: unsafe; may cause birth defects.
Breastfeeding: unsafe; may harm the baby.
Lungs: unknown if safe for patients with lung problems.
Liver: unknown if safe for patients with liver disorders.
Alcohol: unsafe to consume alcohol with Pegstim 6mg Injection.
Driving: unsafe to travel, drive vehicles, or operate heavy machinery after taking Pegstim 6mg Injection.
How to Consume:
Administered subcutaneously by a qualified healthcare professional in a hospital setting.
Dose and frequency decided by your doctor.
If administered at home, read the "Instructions for use" carefully from the package insert.
Storage:
Store in a refrigerator (2°C – 8°C).
Do not freeze.
Discard if stored at room temperature for more than 48 hours.
Keep out of reach from children and pets.
FAQs:
Difference between Pegstim 6mg Injection pre-filled syringe and on-body injector: The on-body injector is a small, lightweight delivery system applied to the skin during your chemo appointment. It is automatically designed to inject the dose under your skin (subcutaneously) whereas the pre-filled syringe contains the Pegstim 6mg Injection medicine, and it should be injected by your healthcare provider or you manually.
Symptoms to notify the physician: Inform your physician if you are experiencing any symptoms of swelling in the face, feet, hands, and abdomen, difficulty in breathing, sudden drop in blood pressure, left abdominal pain, weakness, and skin rashes.
Pegstim 6mg Injection package insert: The FDA provides a package insert, which summarizes the relevant scientific information needed for healthcare practitioners and patients to use the drug safely and effectively. The package insert contains safety information, instruction for use, and other information.
Who should not take Pegstim 6mg Injection: Pegstim 6mg Injection is not indicated for everyone. Do not take this Injection if you are allergic to pegfilgrastim. Filgrastim or any of the other ingredients in this Injection.
Will Pegstim 6mg Injection affect my kidneys? This Injection may affect your kidneys. Regular kidney function tests will be taken to monitor your kidney functions. Inform your physician if you have any kidney problems.
Can I breastfeed while taking Pegstim 6mg Injection? No, this Injection secretes in small amounts in breast milk. Pegstim 6mg Injection can cause harm to your baby. Please consult your doctor if you are breastfeeding.